Press Releases

09.24.2019

Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019

09.24.2019

Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

09.20.2019

CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

09.19.2019

Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio

09.17.2019

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts

09.09.2019

Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants

08.21.2019

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

08.21.2019

Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina

08.20.2019

The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance

08.02.2019

Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis

08.01.2019

Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company

07.31.2019

BioInvent announces selection of first target discovered by BioInvent’s proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc.